Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

e company's business. The company's 2013 financial guidance is also being provided on both a reported and a non-GAAP basis.

"Lilly delivered solid financial results in the first quarter of 2013 despite numerous headwinds, as growth in several key products and regions offset the post-patent decline in Zyprexa, a weaker Japanese yen and a slowdown in parts of our animal health business," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We also continued to maintain strict expense controls this quarter. Most importantly, we have remained focused on advancing our late-stage pipeline, and are pleased to announce that we have received Fast Track designation from the FDA and have initiated a rolling submission for ramucirumab. Together with the recent submission of empagliflozin, these are the first two of what could be up to five U.S. regulatory submissions this year."

Key Events Over the Last Three Months

  • The company and its partner, Boehringer Ingelheim, submitted a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin to the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus in adults. In addition, the European Medicines Agency accepted for review a marketing authorization application for empagliflozin.
  • The company received Fast Track designation from the FDA and initiated a rolling submission for ramucirumab as monotherapy treatment in second-line gastric cancer.
  • The company announced that the primary endpoints related to reduction in HbA1c were met in the Phase 3 AWARD-2 and AWARD-4 studies for dulaglutide, an investigational GLP-1 receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
  • The Phase III rheumatoid arthritis (RA) program for tabalumab was discontinued due to lack of efficacy. The decision was not based on safety concerns. The tabalumab Phase II
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. DiversityInc Names Lilly a Top Company for Diversity
    2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
    4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
    5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
    6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
    7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
    8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
    10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
    11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
    (Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
    (Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
    Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
    (Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
    (Date:7/9/2014)... the first time, researchers have access to detailed information ... health care. A new study, called Our Health Counts, ... challenges faced by urban Aboriginal people in Canada ... The findings, published today in BMJ Open , ... the general population. , Researchers interviewed 554 First Nations ...
    (Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
    (Date:7/9/2014)... policing injection drug users in Russia might contribute ... A study, conducted by researchers from Boston University ... with St. Petersburg Pavlov State University, sought to ... health outcomes of a cohort of HIV-positive people ... who were arrested by police were more likely ...
    (Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
    Breaking Medicine News(10 mins):Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
    ... are cutting their transportation costs and reducing delivery times, as a ... customs processes. , ... Jericho, NY (Vocus) May 29, ... cutting their transportation costs and reducing delivery times, as a result ...
    ... Clinicians, researchers and scientists from around the world ... (DDW ), the largest and most prestigious gastroenterology ... the McCormick Place Convention Center, Chicago, IL. DDW is ... Institute, the largest and oldest GI society in the ...
    ... ProperSAN FRANCISCO, May 28 The following is a statement ... is a complete vindication for Blue Shield of California. ... It means that our underwriting procedures were fair and ... faith. There was no post-claims underwriting. The evidence ...
    ... to announce the introduction of the new Multi-Gas Plus ... These cartridges are unique because they do not ... can be used to work in environments up to ... OSHA guidelines are followed (service life graphs are available). ...
    ... researchers report that a combination of trastuzumab and neratinib ... receptor (ErbB2) appears active in women with HER2-positive metastatic ... therapies. More than one-quarter of the women in ... the combination therapy. , "I think this is ...
    ... could be targets for treatments, researchers say , , THURSDAY, May ... in the parts of their brains that monitor behaviors and ... vulnerable to addiction to the drug, a new research shows. ... in these regions of the brain when cocaine users were ...
    Cached Medicine News:Health News:Purolator USA Offers Canadian Customs Expertise for Medical Device Exports 2Health News:AGA Institute presents cutting-edge research during DDW 2Health News:AGA Institute presents cutting-edge research during DDW 3Health News:AGA Institute presents cutting-edge research during DDW 4Health News:Draeger Announces New Multi-Gas Plus Cartridge 2Health News:Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer 2Health News:Brain Scans Show Differences in Cocaine Addicts 2
    ... Mumps IgG Enzyme- linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to Mumps virus ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
    The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
    With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
    ... Ultra Laboratory has been uniquely designed ... single facility to integrated networks spanning ... to management reporting and accounts receivable, ... precise laboratory management. All system modules ...
    Medicine Products: